GREENVILLE, S.C.–(BUSINESS WIRE)–docs24, a leading provider of Digital and Print Asset Management Solutions for the Clinical Research sector today announced that it has entered a strategic partnership with Intrinseque Health. Intrinseque Health provides clinical supplies and equipment to investigative sites across the globe. They do this through the implementation of robust clinical supply and equipment … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Patient Monitoring Devices Market Research Report by Product, End User, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Patient Monitoring Devices Market size was estimated at USD 40.08 billion in 2021, USD 45.31 billion in 2022, and is projected to grow … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Real World Evidence Solution Market Research Report by Component (Data Set and Services), Therapeutic Area, End-User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Real World Evidence Solution Market size was estimated at … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Clinical Alarm Management Market Research Report by Product (Bed Alarms, EMR Integration System, and Nurse Call System), Component, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Clinical Alarm Management Market size … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Monkeypox Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Treatment), By End User, By Region” report has been added to ResearchAndMarkets.com’s offering. Global Monkeypox therapeutics market is projected to register growth at a significant CAGR during the forecast period, 2023-2027 The market growth can be attributed to … [Read more…]
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union Submission supported by results from the pivotal Phase 3 EMERALD study showing a statistically significant difference in the efficacy in … [Read more…]
CRYSVITA is the first approved biologic treatment in the EU for patients with TIO who cannot undergo surgical removal of tumours TOKYO, Japan–(BUSINESS WIRE)–Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Cleanroom Technologies Market with COVID-19 Impact, by Product (Fan Filter Units, HVAC, vacuum systems, disinfectants), Construction (Drywall, Hardwall, Softwall), End User (Pharmaceutical, Biotechnology, Medical device manufacturers) – Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering. The cleanroom technologies market is projected to reach USD 9.6 billion by 2026 from USD … [Read more…]
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently approved in Canada under the brand name KORSUVA® Regulatory decisions in Australia and Singapore expected by the end of 2022 ST. GALLEN, Switzerland & STAMFORD, Conn.–(BUSINESS WIRE)–Vifor Fresenius Medical … [Read more…]
Vegzelma™ offers European patients living with certain types of breast, lung, renal, colon, rectum, ovarian and cervical cancers a new, safe, and effective treatment option at an affordable price Approval is based on clinical trial data demonstrating Vegzelma™ is highly similar to Avastin®1 (bevacizumab) Vegzelma™ is Celltrion’s third oncology biosimilar approved by the European Commission … [Read more…]
